Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial, an efficacy‐driven translational modeling approach was propos...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wenyuan, Friese‐Hamim, Manja, Johne, Andreas, Stroh, Christopher, Klevesath, Manfred, Falchook, Gerald S., Hong, David S., Girard, Pascal, El Bawab, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129711/
https://www.ncbi.nlm.nih.gov/pubmed/33818908
http://dx.doi.org/10.1002/psp4.12602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129711/
https://www.ncbi.nlm.nih.gov/pubmed/33818908
http://dx.doi.org/10.1002/psp4.12602

Ejemplares similares